2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Bradley R. Corr, MD, discusses the utilization of molecular profiling in endometrial cancer.
Bradley R. Corr, MD, assistant professor of gynecologic oncology, Division of Gynecologic Oncology, University of Colorado Anschutz Medical Campus, UCHealth, discusses the utilization of molecular profiling in endometrial cancer.
Molecular profiling has quickly evolved to be the standard of care for patients with endometrial cancer, Corr says. This is because molecular profiling continues to dictate thoseappropriate therapies for patients as the field advances significantly, Corr explains. Moreover, the National Comprehensive Cancer Network guidelines recommend molecular testing for patients with standard, mismatch repair deficient, POLE-mutated, and p53-mutated endometrial cancers, Corr adds.
As these recommendations develop, molecular markers are being identified, as areefficacious therapies targeted toward these molecular markers, Corr continues. This is helping to not only dictate which therapies are used, but also which tumors don't require therapy, Corr says. As such, molecular testing is informing clinical trial development, as well as informing treatment selecting for patients with endometrial cancer, Corr concludes.